股静脉转位动静脉瘘:上肢通路耗竭血透患者的持久选择
结果显示6个月成熟率88.9%,1年一期和二期通畅率分别为65.9%和94.7%,但伤口并发症率达19%。作者认为FVT虽伤口并发症较高,但成熟率和通畅率优异,应积极考虑用于无上肢通路选项的患者。
要点
- 上肢通路耗竭患者可考虑自体股静脉转位动静脉瘘。
- FVT术后6个月成熟率88.9%,1年二期通畅率94.7%。
- 术后30天伤口并发症发生率19%,需注意伤口管理。
核心结论
- 自体股静脉转位动静脉瘘在上肢无通路选项中成熟率优异且1年通畅率良好,虽伤口并发症显著但仍应积极考虑。
主要发现
- 平均年龄55.3±11.1岁,女性23.8%,非裔美国人71.4%,中位BMI 27.1 kg/m2(范围17-46 kg/m2)。
- 合并症包括高血压100%、糖尿病61.9%、冠心病57.1%、充血性心衰47.6%、肥胖38.1%。
- 13例(61.9%)既往上肢通路超过3次,17例(81%)术前影像证实中心静脉狭窄或闭塞。
- 平均手术时间250分钟(范围144-406分钟),估计失血量140.5 mL,20例(95.2%)行吻合前缩窄。
- 4例(19%)30天内重返手术室,30天心脏和伤口并发症发生率分别为9.5%和19%,1例(4.8%)7个月时因远端动脉缺血需血运重建,无通路相关感染导致结扎,30天无死亡。
临床怎么用
- 对于上肢血管通路耗竭的终末期肾病患者,可考虑行自体股静脉转位动静脉瘘。
- 术前应评估中心静脉狭窄或闭塞情况,并告知患者伤口并发症风险较高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Access surgeons often encounter patients with end-stage renal disease who have exhausted all upper extremity hemodialysis access options. Although the lower extremity is often the next alternative, prosthetic lower extremity access can be prone to infectious complications and historically has poor patency. We describe our contemporary experience with an autogenous femoral vein transposition (FVT) arteriovenous fistula. METHODS: All FVTs performed at an academic medical center from 2006 to 2018 were analyzed. FVTs were placed after upper extremity access was deemed no longer possible by the treating surgeon. Patient demographics, comorbidities, and access history were described, and perioperative and short-term outcomes, including maturation, were analyzed. RESULTS: Twenty-one patients treated with FVT were identified. The mean age was 55.3 ± 11.1 years; 23.8% were female, and 71.4% were African American. The median body mass index was 27.1 kg/m2 (range, 17-46 kg/m2). Comorbidities included hypertension (100%), diabetes (61.9%), coronary artery disease (57.1%), congestive heart failure (47.6%), and obesity (38.1%). Twenty patients had at least one prior arm access, whereas 13 patients (61.9%) had more than three prior arm accesses. Seventeen patients (81%) had central venous stenosis or occlusion confirmed on preoperative imaging. The mean operative time was 250 minutes (range, 144-406 minutes), and estimated blood loss was 140.5 mL. Preanastomotic tapering was performed in 20 (95.2%) patients. Four (19%) patients returned to the operating room within 30 days. Thirty-day postoperative cardiac and wound complications occurred in 9.5% and 19% of patients, respectively. Distal arterial ischemia requiring revascularization occurred in one (4.8%) patient at 7 months. There were no access-related infections that resulted in fistula ligation. There was no mortality at 30 days. Successful fistula maturation rate at 6 months was 88.9%. At 1 year, primary and secondary patency rates were 65.9%, and 94.7%, respectively. CONCLUSIONS: Although autogenous FVT performed in patients without upper extremity options has a significant wound complication rate, it is associated with an outstanding maturation rate and excellent patency rates at 1 year. This access should be readily considered in hemodialysis patients without upper extremity access options.
引用
- Farber A, Cheng TW, Nimmich A, et al. Femoral vein transposition is a durable hemodialysis access for patients who have exhausted upper extremity options. J Vasc Surg. 2019. PMID: 31492614. doi:10.1016/j.jvs.2019.07.062
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。